This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
Here's Why You Should Retain Ventas (VTR) in Your Portfolio
by Zacks Equity Research
Rise in healthcare spending by senior citizens, accretive investments in the R&I business and a solid balance sheet will aid Ventas (VTR). Yet, stiff competition and higher interest rates are woes.
Welltower (WELL) Q2 FFO & Revenues Beat, SHOP Occupancy Up
by Zacks Equity Research
Welltower's (WELL) Q2 results outpace estimates with solid top-line growth. The seniors housing operating portfolio occupancy witnesses significant improvements year over year.
Welltower (WELL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Welltower's (WELL) Q2 earnings are likely to have benefited from occupancy gains in the seniors housing operating portfolio. However, higher expenses in the quarter might have been a deterrent.
Ventas' (VTR) Q2 FFO Meets, Revenues Up Y/Y, SHOP NOI Rises
by Zacks Equity Research
Ventas' (VTR) Q2 results display year-over-year top-line growth aided by solid demand and improving pricing power for the senior housing operating portfolio.
Ventas (VTR) Q2 FFO Meet Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 0% and 1.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The Necessity Retail (RTL) Q2 FFO and Revenues Beat Estimates
by Zacks Equity Research
The Necessity Retail (RTL) delivered FFO and revenue surprises of 7.41% and 16.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ventas (VTR) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ventas' (VTR) Q2 earnings are likely to have benefited from the occupancy growth of its SHOP segment. However, earnings dilution in the triple net and office segments might have been a spoilsport.
Is it Wise to Retain Ventas (VTR) Stock in Your Portfolio?
by Zacks Equity Research
Ventas (VTR) is well-positioned to gain from its diverse healthcare real estate portfolio and a healthy balance-sheet position. Yet, tenant concentration risk and interest rate hikes are major woes.
Ventas' (VTR) Outlook Raised by S&P Global, Rating Maintained
by Zacks Equity Research
S&P Global Ratings upgrades Ventas' (VTR) outlook to stable from negative, highlighting improving fundamentals driven by senior housing recovery. Moreover, it maintains the rating at BBB+.
Welltower (WELL) Q1 FFO Tops, Seniors Housing Occupancy Gains
by Moumita C. Chattopadhyay
Concurrent with Q1 results reflecting the seniors housing occupancy expansion, Welltower (WELL) announces the expansion of its strategic partnership with Oakmont Management Group.
Ventas' (VTR) FFO Beats Estimates in Q1, SHOP Occupancy Rises
by Zacks Equity Research
Ventas' (VTR) Q1 results display improvement in FFO aided by increased occupancy in Senior Housing Operating Portfolio segment.
Ventas (VTR) Surpasses Q1 FFO Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.60% and 2.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ventas (VTR) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
While strength in its Medical Office Building and growing Life Science and Research & Innovation businesses is likely to have aided Ventas (VTR) in Q1, elevated costs might have been a deterrent.
Public Storage (PSA) Tops Q1 FFO Estimates, Reiterates '22 View
by Zacks Equity Research
Public Storage's (PSA) Q1 results reflect an increase in the realized annual rent per available square foot. The company gains from expansion moves.
Is a Surprise Coming for Ventas (VTR) This Earnings Season?
by Zacks Equity Research
Ventas (VTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Chatham Lodging (CLDT) Q1 FFO and Revenues Beat Estimates
by Zacks Equity Research
Chatham Lodging (CLDT) delivered FFO and revenue surprises of 800% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Federal Realty (FRT) This Earnings Season?
by Zacks Equity Research
Federal Realty's (FRT) first-quarter results are likely to gain from continued demand recovery.
What's in the Cards for Realty Income (O) in Q1 Earnings?
by Zacks Equity Research
Realty Income's (O) Q1 results are likely to reflect the benefits of having essential retail tenants in its roster and gains from accretive buyouts.
MGM Growth Properties (MGP) Q1 FFO and Revenues Surpass Estimates
by Zacks Equity Research
MGM Growth (MGP) delivered FFO and revenue surprises of 2.99% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ventas' (VTR) FFO and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Ventas' (VTR) Q4 results reflect better occupancy and sequential growth in its Senior Housing Operating Portfolio segment.
Ventas (VTR) Tops Q4 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.82% and 5.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ventas (VTR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
While higher occupancy levels at senior housing facilities are likely to have aided Ventas (VTR) in Q4, elevated costs might have been a deterrent.
Healthpeak (PEAK) Meets Q4 FFO Estimates
by Zacks Equity Research
Healthpeak (PEAK) delivered FFO and revenue surprises of 0% and 0.23%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why It Is Wise to Retain Ventas (VTR) Stock Right Now
by Zacks Equity Research
Ventas (VTR) is likely to benefit from the positive operating trend in its office segment and senior-housing operations. However, competition from national and local healthcare operators remains a concern.
Here's Why You Should Hold Ventas (VTR) Stock in Your Portfolio
by Zacks Equity Research
Ventas' (VTR) office segment and senior housing operations have upside potential. However, competition from national and local healthcare operators remains a concern.